| abstract |
REFERS TO AN ACYLGUANIDIN COMPOUNDS OF FORMULA I AND II WHERE R1 IS H, ALKYL (C1-C4), ALCOXY (C1-C4), HALOGEN, CN, NR10R1, -O-CH2-CF3, -SOm (CH2) r-CF3 , AMONG OTHERS; R2 IS H, HALOGEN, CN, -SO2CH3, - (S0h) z- (CH2) k-CF3, PHENYL or O-PHENYL, SUBSTITUTED OR NOT, OR HETEROARYL, SUBSTITUTED OR NOT, AMONG OTHERS; R3 AND R4 ARE INDEPENDENTLY H OR F. THE PREFERRED COMPOUNDS ARE: -3-PENTAFLUOROSULFANYLBENZOYLGUANIDINE HYDROCHLORIDE, N- [2- (4-FLUOROPHENOXY) -4-PENTAFLUOROSULFANIL-BENZOYL-5-GUANIDFLUOROSULFANIL-BENZOYL-5-GUANIDFLU-PENZOYL-5-GUANIDFLUOXY-N-GUANIDFLUOROSULPHANIL-BENZOYL-5-GUANIDFLU-5 GUANIDINE, 4-PENTAFLUOROSULFANIL-2-METHTILBENZOYLGUANDINE, AMONG OTHERS. IT ALSO REFERS TO A PROCEDURE FOR ITS ELABORATION. THESE COMPOUNDS INHIBIT THE CELLULAR ANTIPORTER SODIUM-PROTON (Na + / H + EXCHANGER, NHE). THEY ARE SUITABLE AS ANTIARRHYTHMIC MEDICINES WITH A CARDIOPROTECTIVE COMPONENT FOR PROPHYLAXIS AND TREATMENT OF INFARCTION, ANGINA PEAK. ALSO PREVENT PATHOPHYSIOLOGICAL PROCESSES ASSOCIATED WITH DAMAGE INDUCED BY ISCHEMIA |